Shree Ganesh Remedies Ltd
Incorporated in 1995, Shree Ganesh Remedies Ltd is a manufacturer of Pharmaceutical Drug Intermediates for API & Fine Chemicals[1]
- Market Cap ₹ 779 Cr.
- Current Price ₹ 607
- High / Low ₹ 950 / 573
- Stock P/E 33.8
- Book Value ₹ 113
- Dividend Yield 0.00 %
- ROCE 19.5 %
- ROE 17.3 %
- Face Value ₹ 10.0
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
35 | 64 | 49 | 126 | 109 | |
26 | 52 | 35 | 84 | 69 | |
Operating Profit | 9 | 13 | 14 | 42 | 39 |
OPM % | 25% | 20% | 28% | 33% | 36% |
1 | 4 | 2 | 3 | 4 | |
Interest | 0 | 1 | 0 | 1 | 2 |
Depreciation | 1 | 2 | 3 | 6 | 10 |
Profit before tax | 9 | 14 | 13 | 38 | 31 |
Tax % | 28% | 23% | 25% | 26% | 26% |
6 | 10 | 10 | 28 | 23 | |
EPS in Rs | 4.88 | 8.18 | 7.62 | 21.96 | 17.97 |
Dividend Payout % | 18% | 13% | 18% | 2% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 11% |
3 Years: | % |
TTM: | -14% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 17% |
3 Years: | % |
TTM: | -18% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 62% |
3 Years: | 32% |
1 Year: | 2% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | 17% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
Equity Capital | 9 | 9 | 13 | 13 | |
Reserves | 25 | 33 | 109 | 132 | |
1 | 4 | 36 | 38 | ||
7 | 9 | 12 | 8 | ||
Total Liabilities | 41 | 55 | 171 | 192 | |
14 | 20 | 81 | 95 | ||
CWIP | 0 | 0 | 17 | 8 | |
Investments | 4 | 3 | 5 | 18 | |
23 | 32 | 69 | 70 | ||
Total Assets | 41 | 55 | 171 | 192 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
-5 | 5 | 3 | 30 | 31 | |
-0 | -3 | -1 | -33 | -36 | |
-0 | -0 | -1 | 10 | -1 | |
Net Cash Flow | -5 | 1 | 2 | 7 | -6 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
Debtor Days | 101 | 101 | 59 | 75 | |
Inventory Days | 125 | 61 | 156 | 224 | |
Days Payable | 75 | 43 | 51 | 61 | |
Cash Conversion Cycle | 151 | 119 | 164 | 238 | |
Working Capital Days | 149 | 115 | 110 | 202 | |
ROCE % | 35% | 20% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
24h - Audio recording link of May 21, 2025 earnings call shared by Shree Ganesh Remedies.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 24h
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
2d - Q4 FY25 revenue down 14%, EBITDA margin 36.1%, new MoU with Japanese client, capacity expansion underway.
- Announcement under Regulation 30 (LODR)-Investor Presentation 2d
-
Appointment Of Secretarial Auditors And Internal Auditors Of The Company
19 May - Audited FY25 financial results approved; secretarial and internal auditors appointed/re-appointed.
Business Overview:[1]
SGRL is an ISO 14001 certified complex chemical manufacturer, specialising in pharmaceutical intermediates and speciality chemicals.